FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, with or Without Monoclonal Antibodies in Advanced Solid Tumors
NCT06241456
Recruiting
This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +14 locations
Conditions: Advanced Solid Tumor
Register for Updates
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
NCT04029688
Terminated
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with chemotherapy or venetoclax, in pediatric and young adult participants with acute leukemias or solid tumors. This study is divided into three parts: Part 1 will begin with dose escalation of idasanutlin as a single agent in pediatric participants with relapsed or refractory so... Read More
Gender:
ALL
Ages:
Between 0 years and 30 years
Trial Updated:
12/18/2024
Locations: Arkansas Children's Hospital Research Institute, Little Rock, Arkansas +13 locations
Conditions: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
Register for Updates
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
NCT01358877
Completed
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona +555 locations
Conditions: Breast Cancer
Register for Updates
Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation
NCT02161783
Recruiting
This is a guideline for the treatment of graft failure after hematopoietic stem cell transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose total body irradiation (TBI) is designed to promote donor engraftment by day 42 after initial graft failure. The graft will consist of bone marrow or G-CSF mobilized peripheral blood from a haploidentical related donor. The source of stem cells will be determined by the transplant team based on factors such as patient'... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/18/2024
Locations: University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota
Conditions: Primary Graft Failure, Secondary Graft Failure
Register for Updates
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
NCT03571321
Recruiting
This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
12/17/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Register for Updates
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05633615
Recruiting
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may inter... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +75 locations
Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Register for Updates
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
NCT05521984
Recruiting
This is a pilot phase Ib study of the feasibility and safety of dapagliflozin (in addition to standard of care treatment) for the treatment of pediatric patients with recurrent brain tumors and relapsed/refractory solid tumors. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious as an adjunct to front-line chemotherapy assessed by decreased tumor markers mediated by it... Read More
Gender:
ALL
Ages:
Between 6 years and 21 years
Trial Updated:
12/16/2024
Locations: Washington University School of Medicine/St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: Pediatric Brain Tumor, Pediatric Solid Tumor
Register for Updates
Emapalumab Prevention of CAR-T Cell Associated Toxicities
NCT06550141
Recruiting
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel * Emapalumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Register for Updates
Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma
NCT05996185
Recruiting
Single- arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T cell lymphoma including patients with Adult T-cell leukemia/lymphoma (ATLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Yale Cancer Center, Clinical Trials Office, New Haven, Connecticut
Conditions: T Cell Lymphoma
Register for Updates
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
NCT04109066
Completed
A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) early stage breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Local Institution - 0136, Mobile, Alabama +239 locations
Conditions: Breast Cancer
Register for Updates
Scleroderma Treatment With Autologous Transplant (STAT) Study
NCT01413100
Completed
This phase II trial studies how well giving cyclophosphamide and anti-thymocyte globulin together followed by peripheral blood stem cell transplant (PBSCT) and mycophenolate mofetil works in treating patients with systemic scleroderma (SSc). Stem cells are collected from the patient's blood and stored prior to treatment. To store the stem cells patients are given colony-stimulating factors, such as filgrastim (G-CSF) or chemotherapy (cyclophosphamide) to help stem cells move from the bone marrow... Read More
Gender:
ALL
Ages:
70 years and below
Trial Updated:
12/12/2024
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +11 locations
Conditions: Systemic Scleroderma
Register for Updates
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
NCT04187105
Recruiting
Pre-transplant conditioning will include targeted total marrow irradiation (TMI) at a dose of 6Gy. Graft-versus-host disease prophylaxis will include cyclophosphamide 50 mg/kg on Day +3 and 4 along with tacrolimus and mycophenolate mofetil
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/11/2024
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Acute Leukemia, MDS
Register for Updates